Insight Molecular Diagnostics Inc. — Earnings

Most recent reported period: FY2026 (Q1) (filed for period ending 2026-03-31) · sourced from SEC EDGAR

← Calendar (this week)
Next earnings (estimated): Tue, June 30, 2026 — ~44 days away. Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
Recent · last 8 quartersFuture · next 8 quarters
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2026-03-31$32K↓-98.5%$-4M↑+35.7%-13790.6%
2025-12-31$1M↓-23.4%———
2025-09-30$260K↑+126.1%$-11M↑+19.6%-4249.2%
2025-06-30$518K↑+398.1%$-10M↓-115.1%-1900.0%
2025-03-31$2M↑+1114.8%$-7M↑+26.9%-318.0%
2024-12-31$1M↑+373.2%———
2024-09-30$115K↓-73.2%$-13M↓-107.9%-11752.2%
2024-06-30$104K↓-77.5%$-5M↑+45.6%-4453.8%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2026 (Q1)

Revenue
$32K
↓-98.5% -$2M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 47 quarters

margin trajectory tells the operating-leverage story
Gross Margin↓-15.1pts
46.9%
Operating Margin↓-13472.6pts
-13790.6%
Net Margin↓-13094.2pts
-13406.3%

Go deeper

IMDX Sankey — flow of dollars

See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.

Open Sankey

IMDX Key Metrics — EPS, ROE, ROIC

10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.

Open Key Metrics